Viomycin

CHEMBL3085436 Phase 4 Onaylandı Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

685.7 g/mol

LogP

-7.0

Phase

4

Viomycin is a cyclic peptide antibiotic produced by Streptomyces species that inhibits bacterial protein synthesis by binding to the 30S and 50S ribosomal subunits and blocking translocation, with particular activity against mycobacteria including Mycobacterium tuberculosis. It was used as a second-line antituberculosis agent for drug-resistant TB before the development of modern combination regimens. Its nephrotoxicity and ototoxicity limit its clinical application.

Moleküler Ağırlık

685,7000 g/mol

LogP

-7,00

TPSA

393,00 Å²

Lipinski RO5

Başarısız

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@H]([C@H]2C[C@H](O)NC(N)=N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O

InChI

InChI=1S/C25H43N13O10/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48)/b13-7-/t10-,11+,12-,14-,15-,17-,18-/m0/s1

Molecular Formula

C25H43N13O10

HBD / HBA

15 / 13

Döndürülebilir Bağlar

10

Ağır Atomlar

48

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Viomycin is a cyclic peptide antibiotic produced by Streptomyces species that inhibits bacterial protein synthesis by binding to the 30S and 50S ribosomal subunits and blocking translocation, with particular activity against mycobacteria including Mycobacterium tuberculosis. It was used as a second-line antituberculosis agent for drug-resistant TB before the development of modern combination regimens. Its nephrotoxicity and ototoxicity limit its clinical application.

Yes, Viomycin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3085436. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135398671. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Viomycin PillFYI'da

Yapı

Hızlı Veriler

Formül: C25H43N13O10

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.